Tirzepatide
Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)
Potential Benefits
- FDA-approved for type 2 diabetes with superior A1c reduction vs. semaglutide in head-to-head trials
- FDA-approved for chronic weight management with average weight loss of 20-26% in trials (SURMOUNT program)
- Dual GIP/GLP-1 mechanism may provide additive metabolic benefits
- Clinical trials showed improvements in cardiometabolic markers including blood pressure and lipids
- Once-weekly injection with demonstrated patient adherence
Recommended Starting Dose
2.5 mg subcutaneously once weekly (titration starting dose)
Based on published research protocols. Not a prescription.
Dosing Protocol
Titrated gradually: 2.5 mg weekly for 4 weeks, then 5 mg weekly for 4 weeks, with further increases to 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg weekly based on response and tolerance. Slow titration over months is standard. Must be prescribed and monitored by a physician.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Appetite changes and initial weight loss typically begin within 2-4 weeks. The SURMOUNT trials showed progressive weight loss through 72 weeks, with the most rapid loss in the first 36 weeks.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Nausea (common during titration)
- Diarrhea and constipation
- Vomiting
- Abdominal pain and dyspepsia
- Injection site reactions
- Risk of pancreatitis (rare)
- Gallbladder-related events
- Boxed warning for thyroid C-cell tumors (rodent findings)
- Hypoglycemia when combined with insulin or sulfonylureas
- Potential for muscle mass loss
More in Weight Loss
AOD-9604
Advanced Obesity Drug 9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) developed by Monash University in Australia. It was designed to retain the fat-reducing properties of GH without the growth-promoting or diabetogenic effects. While initial clinical trials showed promise for obesity, it did not receive FDA approval as a drug.
Retatrutide
Retatrutide (Triple G Receptor Agonist)
Retatrutide is an investigational triple hormone receptor agonist (GLP-1, GIP, and glucagon receptors) developed by Eli Lilly. By targeting all three incretin and metabolic pathways simultaneously, it has demonstrated unprecedented efficacy in early clinical trials for obesity, resulting in up to 24.2% body weight reduction over 48 weeks—currently surpassing single and dual-agonists in trial comparisons.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.